AB — AB Science SAHealthcare · Drug Manufacturers - Specialty & GenericEURONEXT
€63.5M
Mkt Cap
€74.0M
Ent. Value
-€10.5M
Net Cash
€0.96
52W €1 – €2
€63.5M
Mkt Cap
€74.0M
Ent. Value
-€10.5M
Net Cash
—
P/E TTM
—
PEG
—
P/FCF
—
P/Book
61.8×
P/Sales
—
EV/EBITDA
—
EV/EBIT
199.9×
EV/FCF
69.0×
EV/Sales
-12.9%
Earn Yld
-10.7%
FCF Yld
—
Div Yld
€0.96
·
All values in Euros (EUR)
EUR
FY2024
FY2023
FY2022
FY2021
Revenue
1.07M
970,000
958,000
1.61M
YoY Growth
+10.5%
+1.3%
-40.4%
—
Gross Profit
1.25M
587,000
927,000
1.50M
Gross Margin
116.4%
60.5%
96.8%
93.1%
R&D
3.94M
10.48M
13.35M
11.23M
SG&A
1.93M
1.84M
2.15M
2.74M
EBIT
(6.08M)
(13.43M)
(15.94M)
(13.81M)
EBIT Margin
-567.4%
-1384.4%
-1663.7%
-859.2%
D&A
667,000
2.27M
(81,000)
1.73M
EBITDA
(4.92M)
(7.18M)
(11.60M)
(11.41M)
EBITDA Margin
-458.7%
-740.5%
-1210.3%
-710.1%
Net Income
(7.83M)
(11.98M)
(13.62M)
(14.46M)
Net Margin
-730.5%
-1235.6%
-1421.2%
-900.0%
EPS (diluted)
-€0.15
-€0.24
-€0.29
-€0.30
Shares (dil., M)
76
68
63
65
Company Brief
AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company's lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyotrophic lateral sclerosis, progressive forms of multiple sclerosis, Alzheimer's disease, and indolent systemic mastocytosis, as well as in Phase 2 trial for mast cell activation syndrome and sickle cell disease. It also develops AB8939, a microtubule destabilizer in Phase 1 trial for the treatment of acute myeloid leukemia; and AB12319 in preclinical trial to treat sarcoma and solid tumors. In addition, the company markets its masitinib under the Masivet brand for the treatment of mast cell tumors in dogs in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company's lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyotrophic lateral sclerosis, progressive forms of multiple sclerosis, Alzheimer's disease, and indolent systemic mastocytosis, as well as in Phase 2 trial for mast cell activation syndrome and sickle cell disease. It also develops AB8939, a microtubule destabilizer in Phase 1 trial for the treatment of acute myeloid leukemia; and AB12319 in preclinical trial to treat sarcoma and solid tumors. In addition, the company markets its masitinib under the Masivet brand for the treatment of mast cell tumors in dogs in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
